BiomX Reports Second Quarter 2020 Financial Results and Provides Business Update - Expect to initiate Phase 1a clinical study of BX002 for the treatment of IBD in the third quarter of 2020; pharmacokinetics results expec

Reports Second Quarter 2020 Financial Results and Provides Business Update

Expect to initiate Phase 1a clinical study of BX002 for the treatment of IBD in the third quarter of 2020;

pharmacokinetics results

expected by the end of 2020

On track for Phase 2 cosmetic clinical study of BX001 in acne first quarter of 2021

Cash and equivalents of $70.6 million expected to fund current operating plan through mid-2022

Company to host conference call today at 8:00 a.m. Eastern Time

Ziona, Israel - August 13, 2020 - BiomX Inc. (NYSE : PHGE), a clinical stage company developing natural

and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business

update for the second quarter ended June 30, 2020.

proof of concept clinical results for our phage therapy cocktail BX001 in acne-prone skin earlier this year, we continue to advance

the development of multiple phage therapy candidates that have the potential to improve treatment in diverse disease areas,"

commented Jonathan Solomon, Chief Executive Officer of BiomX. "These candidates are designed with the ability to selectively

reduce pathogenic bacterial strains without disrupting beneficial bacteria. Our BX002 program for the treatment of inflammatory

bowel disease (IBD) is on track to begin clinical development in the third quarter, with the initial goal of demonstrating an

ability to deliver viable phage to the lower gastrointestinal tract. We expect to report pharmacokinetics and safety data from

the study by the end of 2020. This is an important step in our clinical development plans for both IBD and primary sclerosing

cholangitis (PSC). The Phase 1a results are expected to inform the design of a Phase 1b/2a study aimed at evaluating the efficacy

of BX002 in reduction of the target bacteria."

Highlights and Key Upcoming Milestones

for the Treatment of Inflammatory Bowel Disease

for the Cosmetic Market for the Appearance of Acne-Prone Skin

for the Treatment of Primary Sclerosing Cholangitis

Therapy for Tumor-Targeted Delivery in Cancer

Quarter 2020 Financial Results

management will host a conference call and webcast today at 8:00 a.m. ET to report financial results for the second quarter of

2020 and provide business updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.), 1-809-406-247 (Israel)

or 1-201-389-0898 (international). A live and archived webcast of the call will be available in the Investors section of the company's

website at www.biomx.com.

Bacteriophage, or phage, are viruses that target bacteria and are considered inert to mammalian cells. Specific phage can

target and kill specific bacterial species or strains without disrupting other bacteria or the healthy microbiota. All of BiomX's

phage-based product candidates derive from its proprietary platform, which is first used to discover and validate the association

and biologic rationale of specific bacterial strains with human diseases or conditions, and is then used to develop rationally-designed

phage combinations ("cocktails") of naturally occurring or synthetic phage to target pathogenic bacteria. The phage

cocktails contain multiple phage with complementary functions optimized through in vitro and in vivo testing.

is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy

bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease

(IBD), primary sclerosing cholangitis (PSC), and colorectal cancer (CRC). BiomX discovers and validates proprietary bacterial

targets and customizes phage compositions against these targets.

This press release contains express or implied "forward-looking statements" within the meaning of the "safe

harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified

by words such as: "target," "believe," "expect," "will," "may," "anticipate,"

"estimate," "would," "positioned," "future," and other similar expressions that

predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX discusses

its clinical and pre-clinical development program, including timing and milestones thereof, the design and potential of its product

candidates, the potential effect of COVID-19 on BiomX's business, sufficiency of financial resources and how long BiomX's

cash and cash equivalents are expected to fund its operations BiomX is making forward-looking statements. Forward-looking statements

are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management's current

beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties,

risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX control. Actual results

and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, investors should not rely

on any of these forward-looking statements and should review the risks and uncertainties described under the caption "Risk

Factors" in BiomX's most recent Annual Report on Form 10-K and additional disclosures BiomX makes in its filings with

the Securities and Exchange Commission (the "SEC"), which are available on the SEC's website at www.sec.gov.

Forward-looking statements are made as of the date of this press release, and BiomX expressly disclaims any obligation or undertaking

to update forward-looking statements.

VP Investor Relations and Strategy

Allan, Solebury Trout